GLP-1 Maintenance: Staying On, Stepping Down, and the Long Game

You reached your dose. The weight came down. Now what — do you stay here forever, taper off, or stop? This is one of the least-discussed and most-searched questions in the whole GLP-1 journey, and it’s surrounded by more wishful thinking than almost any other. Here’s what the evidence actually supports, and — just as important — where it runs out.

This is educational content, not medical advice. Do not start, stop, or change your dose without talking to the prescriber who manages your treatment. The trial figures below come from studies of FDA-approved brand-name medications (Wegovy, Zepbound) and do not apply to compounded semaglutide or tirzepatide, which are not FDA-approved and were not studied in these trials.

First, what “maintenance” really means

There’s a common misconception that “maintenance dose” means a lower dose you drop to once you’ve lost the weight. It doesn’t.

On the FDA labels, the maintenance dose is the target dose you titrate up to and stay on:

• Zepbound (tirzepatide): maintenance dosages are 5 mg, 10 mg, or 15 mg once weekly. The 2.5 mg starting dose is explicitly for initiation and not intended for maintenance.
• Wegovy (semaglutide): the recommended maintenance dose is 2.4 mg weekly, with a 1.7 mg maintenance option if 2.4 mg isn’t tolerated.

In both cases your prescriber selects the maintenance dose based on your treatment response and tolerability. And notably, neither label sets a stop date — obesity is treated as a chronic condition, which is a strong hint about how long these are meant to be used.

The evidence on staying on vs. stopping

This is the part with real, high-quality data — and it’s sobering.

Semaglutide (STEP 4, a randomized trial): after everyone lost weight during a 20-week run-in, half continued the medication and half switched to placebo. Over the next ~11 months, the group that continued lost a further 7.9%, while the group that stopped regained 6.9% — a treatment difference of nearly 15 percentage points of body weight.

Tirzepatide (SURMOUNT-4, a randomized trial): same design. Those who continued lost another ~5.5%; those who stopped regained about 14% of body weight over the following year. Nearly 90% of people who continued kept off at least 80% of their weight loss — versus about 17% of those who stopped.

Longer follow-up (STEP 1 extension): a year after stopping semaglutide, people had regained about two-thirds of the weight they’d lost.

The through-line: these medications manage the biology of appetite while you take them. Stop, and for most people appetite — and weight — return. That’s not weakness; it’s the condition reasserting itself, which is exactly why obesity medicine increasingly frames GLP-1s as long-term therapy rather than a short course.

The honest gap: “stepping down” to a lower dose

Here’s where the internet gets ahead of the science. The appealing idea is: taper to a smaller or less-frequent dose and hold your loss at lower cost with fewer side effects. Does it work?

We don’t really know yet — and anyone who tells you they’re certain is guessing.

• There is no FDA-approved taper-to-maintain protocol, and the labels don’t describe one.
• There is no large trial showing a reduced or extended-interval dose maintains weight loss.
• The only supportive data are small, early, observational reports — hypothesis-generating, not proof.
• Meanwhile, the strong randomized evidence above is about fully stopping, which caused substantial regain. Whether a partial step-down avoids that is largely untested.

So the honest position is: a lower “maintenance” dose might work for some people, but it’s an individualized, monitored experiment — one to run with your prescriber watching, not a plan to self-direct from a forum thread. If your goal is fewer side effects or lower cost, that’s a completely reasonable thing to raise with your clinician; it’s just not something this article (or any article) can hand you a schedule for.

What you can control: protect the results

Whatever you and your prescriber decide about dose, these are the levers with real support:

• Protein. A meaningful share of GLP-1 weight loss — studies suggest roughly a quarter to nearly half — can come from lean (including muscle) mass. Sports-nutrition guidance supports adequate protein (commonly ~1.2–2.0 g/kg/day) to help protect it. See our protein target guide.
• Resistance training. The single most effective way to signal your body to keep muscle during and after weight loss. Start with our muscle-preservation guide.
• Sleep and stress. Both influence appetite and adherence — unglamorous, but they matter more over a long maintenance horizon.

None of these replace the medical conversation, but they’re the parts that are genuinely in your hands, and they matter more the longer you’re on this path.

The bottom line

Maintenance isn’t an afterthought — it’s most of the journey. The evidence says continuing tends to hold results and stopping tends to reverse them; the “maintenance dose” is your target dose, not a consolation dose; and tapering down is a real question with a real evidence gap, best explored with your prescriber rather than a spreadsheet from strangers. Get the muscle-protecting habits locked in now, and bring the dose question to the person who can actually monitor it.

Thinking about the cost side of staying on long-term? Compare honest, all-in provider pricing on our provider comparison, or map your options with the provider match tool.